Vasiljevic Alexandre, Jouanneau Emmanuel, Trouillas Jacqueline, Raverot Gérald
INSERM U1028, CNRS UMR5292, Neuro-oncology and Neuroinflammation Team, Lyon, Neuroscience Research Center, Lyon, France -
Minerva Endocrinol. 2016 Sep;41(3):377-89. Epub 2016 Mar 4.
More than just the confirmation of an endocrinological diagnosis, the pathological analysis of pituitary endocrine tumors may contribute to bring crucial information in prognosis as well as useful insights in therapeutic management. Taken individually, parameters such as histopathological subtyping, Ki-67-labelling or P53 immunoexpression cannot accurately predict the outcome of patients affected by such tumors. Conversely, "mixed" classification integrating invasion assessment by imaging to histopathological diagnosis may give critical prognostic information and help the clinician in identifying those aggressive tumors that will require a careful follow-up and a more vigorous postoperative treatment. Analysis of theranostic factors such as O6-methylguanine-DNA methyl-transferase or somatostatin receptor expression may guide the choice of postoperative treatment.
垂体内分泌肿瘤的病理分析不仅仅是内分泌诊断的确认，还可能有助于提供预后的关键信息以及治疗管理方面的有用见解。单独来看，诸如组织病理学亚型、Ki-67标记或P53免疫表达等参数无法准确预测此类肿瘤患者的预后。相反，将影像学侵袭评估与组织病理学诊断相结合的“混合”分类可能会提供关键的预后信息，并帮助临床医生识别那些需要密切随访和更积极术后治疗的侵袭性肿瘤。对O6-甲基鸟嘌呤-DNA甲基转移酶或生长抑素受体表达等治疗诊断因素的分析可能会指导术后治疗的选择。
